Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MDK-703 + unspecified immune checkpoint inhibitor |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MDK-703 | MDK 703|MDK703 | MDK-703 is an Fc-peptide fusion that activates the IL-7 receptor, potentially leading to enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2066). | ||
unspecified immune checkpoint inhibitor | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05716295 | Phase Ib/II | MDK-703 + unspecified immune checkpoint inhibitor MDK-703 | A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1) | Terminated | USA | 0 |